Erratum: Decreased expression of ferroportin in prostate cancer ( Oncology Letters (2015) 10 (913-916) DOI: 10.3892/ol.2015.3363);Decreased expression of ferroportin in prostate cancer

Oncology Letters

Volumn 10, Issue 2, 2015, Pages 913-916

  Xue, Dong ^a   Zhou, Cui Xing ^a   Shi, Yun Bo ^b   Lu, Hao ^a   He, Xiao Zhou ^a  

^a SOOCHOW UNIVERSITY   (China)

^b CHANGZHOU INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Benign prostatic hyperplasia; Ferroportin; Hepcidin; Prostate cancer

Indexed keywords

FERROPORTIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84931326938     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2021.12518     Document Type: Erratum

References (16)

1. Ye L, Kynaston HG and Jiang WG: Bone metastasis in prostate cancer: Molecular and cellular mechanisms. Int J Mol Med 20: 103-111, 2007.
2. Aihara M, Lebovita RM, Wheeler TM, Kinner BM, Ohori M, and Scardino PT: Prostate specific antigen and gleason grade: An immunohistochemical study of prostate cancer. J Urol 151: 1558-1564, 1994.
3. Melchior SW and Brawer MK: Role of transrectal ultrasound and prostate biopsy. J Clin Ultrasound 24: 463-471, 1996.
4. Torti SV and Torti FM: Ironing out cancer. Cancer Res 71: 1511-1514, 2011.
5. Nemeth E and Ganz T: Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26: 323-342, 2006.
6. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK and Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of iron regulatory hormone hepcidin. J Clin Invest 113: 1271-1276, 2004.
7. Pogribny IP: Ferroportin and hepcidin: a new hope in diagnosis, prognosis and therapy for breast cancer. Breast Cancer Res 12: 314, 2010.
8. Pinnix ZK, Miller LD, Wang W, et al: Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2: 43-56, 2010.
9. Gleason DF: Histologic grading of prostatic carcinoma. In: Pathology of the prostate (Contemporary Issues in Surgical Pathology). Bostwick MD and David G (eds). Churchill Livingstone, New York, pp 83-87, 1990.
10. Cairo G, Bernuzzi F and Recalcati S: A precious metal: Iron, an essential nutrient for all cells. Genes Nutr 1: 25-39, 2006.
11. Merlot AM, Kalinowski DS and Richardson DR: Novel chelators for cancer treatment: Where are we now? Antioxid Redox Signal 18: 973-1006, 2013.
12. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, et al: Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2: 43-56, 2010.
13. Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, Hurren R, Jitkova Y, Gronda M, Isaac M, et al: Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Res 71: 7628-6737, 2011.
14. Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL and Miller JL: Hepcidin, anaemia and prostate cancer. BJU Int 107: 678-9, 2011.
15. De Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, Sundquist WI, Ganz T, Musci G and Kaplan J: The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 18: 2569-2578, 2007.
16. Ellervik C, Tybjaerg-Hansen A and Nordestgaard BG: Risk of cancer by transferrin saturation levels and haemochromatosis genotype: Population-based study and meta-analysis, J Intern Med 271: 51-63, 2012.